Профилактическая гемостатическая терапия препаратом Фейба у больных ингибиторной формой гемофилии
Т. Ю. Полянская, V. Yu. Zorenko · Гематология и трансфузиология · 2014
The development of allogenic antibodies to factor VIII (FVIII) or FIX is one of the most grave complications of substitute therapy for hemophilia. Therapy of bleedings in these patients is carried out by drugs with the shunting mechanisms of action, such as anti-inhibitory coagulant complex (Faiba®, Baxter, Austria) or recombinant activated factor VII (NovoSeven, Coagulyl VII). Both drugs effectively arrest hemorrhagic episodes in patients with inhibitory hemophilia. Today a preventive approach to therapy of hemorrhages in patients with inhibitory hemophilia is actively introduced. It consists in the use of drugs with the shunting mechanism of action. Two international clinical studies have demonstrated that preventive haemostatic therapy with Faiba is safe and effective in patients with inhibitory hemophilia, reducing significantly the number of spontaneous hemorrhages and thus preventing the development or progress of hemophilic arthropathy and improving the patients' quality of life.
Cited by 0 works.